ACTC: meantime, ACTC plods along as fast as possible, considering finances, with it's so-called stem cell therapy toward a therapy for dry eye AMD, with product now in 3 rd cohort of Phase I trial. DSMB continues to voice go-ahead seeing no safety or futility concerns, and ACTC itself has been optimistic. I am personally betting heavily here on ACTC, today's downturn notwithstanding. Posted today from Rome.
Market Data 
Markets 
AI
